Enovis Corporation $ENOV Shares Sold by Stephens Inc. AR

Stephens Inc. AR cut its position in shares of Enovis Corporation (NYSE:ENOV) by 89.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,068 shares of the company’s stock after selling 81,796 shares during the quarter. Stephens Inc. AR’s holdings in Enovis were worth $305,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after buying an additional 367 shares during the period. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Enovis in the 2nd quarter valued at about $46,000. SJS Investment Consulting Inc. boosted its position in shares of Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Enovis by 235.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after purchasing an additional 1,195 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Shares of NYSE:ENOV opened at $23.05 on Wednesday. The company’s fifty day moving average is $27.53 and its two-hundred day moving average is $29.47. The company has a market cap of $1.32 billion, a P/E ratio of -0.97 and a beta of 1.52. Enovis Corporation has a 12-month low of $22.98 and a 12-month high of $49.38. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, November 6th. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $548.91 million during the quarter, compared to analysts’ expectations of $538.61 million. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.Enovis’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 earnings per share. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Equities analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Insider Activity

In related news, insider John Kleckner acquired 2,468 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were purchased at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the transaction, the insider owned 12,302 shares of the company’s stock, valued at approximately $372,996.64. This trade represents a 25.10% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total transaction of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Wells Fargo & Company increased their price objective on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. BTIG Research started coverage on Enovis in a research note on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective for the company. Canaccord Genuity Group cut their target price on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.